Hanall Biopharma Co., Ltd. (009420.KS) Stock
Hanall Biopharma Co., Ltd.

Company profile
Hanall Biopharma reported revenue of 155.18 billion KRW for fiscal year 2025, up 11.7% from fiscal year 2024. In Q1 2026 (the quarter ended March 31, 2026) revenue was 40.03 billion KRW, up 10.7% from a year before. South Korea was its largest region in fiscal year 2025, with 95% of revenue. In Q1 2026 it reported net income of 275.00 million KRW, against a net loss of 207.51 million KRW a year earlier. Our analysis of its filings shows revenue growing from 134.91 billion KRW in fiscal year 2023 to 155.18 billion KRW in fiscal year 2025, 7.3% a year on average. Hanall Biopharma reports about 287 full-time employees.
What stands out
- It reported a net loss in each of its last 2 fiscal years, after a profit of 3.51 billion KRW in fiscal year 2023; the loss widened from 1.80 billion KRW in fiscal year 2024 to 5.56 billion KRW in fiscal year 2025.
- Its net profit margin over the last four reported quarters was -15.3%, against a median of 9.9% for 6 listed companies of similar size in its industry.
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Hanall Biopharma Co., Ltd.
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, functional dyspepsia, diabetes, bacterial infections, peripheral vascular disorders, hypertension, chronic heart failure, skin diseases, hypoproteinemia, diabetic polyneuritis, ulcers, high blood pressure, arthritis, endocrine disorders, spasms, insomnia, muscle pain, hypoproteinemia, gastroesophageal reflux disease, allergic rhinitis, conjunctivitis, dermatitis, chronic urticaria, cholesterol cholelithiasis, gastritis, neurological diseases, erectile dysfunction, hyperphosphatemia, urinary tract infection, spastic paralysis, fungal infections, dysmenorrhea, hypercholesterolemia, constipation, abdominal distension, abdominal fermentation in the intestines, neuralgia, capillary weakness, post-phlebitis syndrome, irritable bowel syndrome, spastic colon, and hemorrhoids, as well as vitamin D, vitamin B1, vitamin B12, and calcium deficiency. It develops products in the fields of ophthalmology, immunology, oncology, and neurology, such as HL192 for Parkinson's disease; HL036 for dry eye disease; HL161 for myasthenia gravis, thyroid eye disease, warm autoimmune hemolytic anemia, neuromyelitis optica, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, and graves' disease; and HL187 and HL186 for immuno-oncology. The company was founded in 1973 and is headquartered in Daejeon, South Korea.
Largest shareholders
- Daewoong Pharmaceutical Co., Ltd30.85%
- National Pension Service of Korea10.84%
- Hanall Biopharma Co., Ltd.2.65%
- Seung-Kook Park0.3642 %0.36%
- Seung-Won Jeong0.0619 %0.06%
Share of the company, as of September 25, 2026
Leadership
- Seung-Kook Park M.B.A., Ph.D. — Co-CEO & Director, 62
- Su-Jin Park — Co-CEO, VP & Director, 53
- Christopher W. Slavinsky — Chief Business Development & Legal Officer, 52
- Nam-Yong Cho — Senior Executive Director of Sales & Marketing and Senior Managing Director, 71
- Jae-Seung Yoon — C.V.O, 63
In the news
- Discovering Hanall Biopharma And Two Other Asian Stocks Estimated Below Intrinsic Value
- HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program
- HanAll Biopharma's Licensed Partner in China Announces Positive Topline Phase 3 Results for Batoclimab in Myasthenia Gravis
- HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities
How much revenue does Hanall Biopharma make?
Hanall Biopharma reported 155.18 billion KRW in revenue for fiscal year 2025, up 11.7% from 138.94 billion KRW in fiscal year 2024. In Q1 2026 revenue was 40.03 billion KRW.
Where does Hanall Biopharma make most of its revenue?
South Korea: 95% of revenue by region in fiscal year 2025, followed by Export (5%).
What companies are similar to Hanall Biopharma?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Alteogen Inc. (196170.KQ), Yuhan Corporation (000100.KS), Hanmi Pharm. Co., Ltd. (128940.KS), LigaChem Biosciences Inc. (141080.KQ).
Has Hanall Biopharma made a profit in recent years?
Net income by fiscal year: FY2021, 8.90 billion KRW; FY2022, 251.47 million KRW; FY2023, 3.51 billion KRW; FY2024, a loss of 1.80 billion KRW; FY2025, a loss of 5.56 billion KRW. It reported a net loss in 2 of these 5 years.
How does Hanall Biopharma's profit margin compare with similar companies?
Net profit margin over the last four reported quarters: Hanall Biopharma, -15.3%; Alteogen Inc. (196170.KQ), 75.5%; Yuhan Corporation (000100.KS), 10.4%; Hanmi Pharm. Co., Ltd. (128940.KS), 0.0%; LigaChem Biosciences Inc. (141080.KQ), -180.9%; Hugel, Inc. (145020.KQ), 26.4%; Celltrion Pharm, Inc. (068760.KQ), 9.5%.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Hanall Biopharma Co., Ltd. (009420.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/009420.KS